For benefits plan sponsors worried about the increasing costs of their plans, the legislation regarding generic drug price reductions (currently implemented in five provinces) may seem like a saving grace.
But not so fast, warns Shawn O’Brien, senior consultant, health and benefits, with Aon Hewitt. He warns that the savings might not be as high as you think, since some drugs aren’t subject to the regulations, and expensive drugs such as biologics are becoming more the norm, rather than the exception.
The trend line is moving up, and plan sponsors need new solutions.
In this BenefitsCanadaTV interview, O’Brien shares his thoughts on how plan sponsors can contain costs, and suggests possible solutions such as re-examining the terms of your contract and implementing higher deductibles.
Watch the video to find out what O’Brien had to say about controlling your costs through plan design.